<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">45457</article-id><article-id pub-id-type="doi">10.7554/eLife.45457</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-129685"><name><surname>Silva</surname><given-names>M Catarina</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5421-6673</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-130361"><name><surname>Ferguson</surname><given-names>Fleur M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4091-7617</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-130362"><name><surname>Cai</surname><given-names>Quan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-113759"><name><surname>Donovan</surname><given-names>Katherine A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-130363"><name><surname>Nandi</surname><given-names>Ghata</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-130364"><name><surname>Patnaik</surname><given-names>Debasis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83473"><name><surname>Zhang</surname><given-names>Tinghu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78747"><name><surname>Huang</surname><given-names>Hai-Tsang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4244-2304</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-130367"><name><surname>Lucente</surname><given-names>Diane E</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-130368"><name><surname>Dickerson</surname><given-names>Bradford C</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-8716"><name><surname>Mitchison</surname><given-names>Timothy J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-113129"><name><surname>Fischer</surname><given-names>Eric S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7337-6306</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4531"><name><surname>Gray</surname><given-names>Nathanael S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5354-7403</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" corresp="yes" id="author-126262"><name><surname>Haggarty</surname><given-names>Stephen J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7872-168X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf8"/></contrib><aff id="aff1"><institution content-type="dept">Chemical Neurobiology Laboratory</institution>, <institution>Massachusetts General Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Cancer Biology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Molecular Neurogenetics Unit</institution>, <institution>Massachusetts General Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">MGH Frontotemporal Disorders Unit</institution>, <institution>Massachusetts General Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Systems Biology</institution>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1065"><name><surname>Cravatt</surname><given-names>Benjamin F</given-names></name><role>Reviewing editor</role><aff><institution>The Scripps Research Institute</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>nathanael_gray@dfci.harvard.edu</email> (NG);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>shaggarty@mgh.harvard.edu</email> (SH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>03</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e45457</elocation-id><history><date date-type="received"><day>23</day><month>01</month><year>2019</year></date><date date-type="accepted"><day>23</day><month>03</month><year>2019</year></date></history><permissions><copyright-statement>Â© 2019, Silva et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Silva et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-45457-v1.pdf"/><abstract><p>Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas. Positron emission tomography (PET) tracers that bind to pathological tau are used in diagnosis, but there are no current therapies to eliminate these tau species. We employed targeted protein degradation technology to convert a tau PET-probe into a functional degrader of pathogenic tau. The hetero-bifunctional molecule QC-01-175 was designed to engage both tau and Cereblon (CRBN), a substrate-receptor for the E3-ubiquitin ligase CRL4<sup>CRBN</sup>, to trigger tau ubiquitination and proteasomal degradation. QC-01-175 effected clearance of tau in frontotemporal dementia (FTD) patient-derived neuronal cell models, with minimal effect on tau from neurons of healthy controls, indicating specificity for disease-relevant forms. QC-01-175 also rescued stress vulnerability in FTD neurons, phenocopying CRISPR-mediated <italic>MAPT</italic>-knockout. This work demonstrates that aberrant tau in FTD patient-derived neurons is amenable to targeted degradation, representing an important advance for therapeutics.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21NS085487</award-id><principal-award-recipient><name><surname>Silva</surname><given-names>M Catarina</given-names></name><name><surname>Lucente</surname><given-names>Diane E</given-names></name><name><surname>Dickerson</surname><given-names>Bradford C</given-names></name><name><surname>Haggarty</surname><given-names>Stephen J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Tau Consortium</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Silva</surname><given-names>M Catarina</given-names></name><name><surname>Nandi</surname><given-names>Ghata</given-names></name><name><surname>Patnaik</surname><given-names>Debasis</given-names></name><name><surname>Haggarty</surname><given-names>Stephen J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>F-Prime Biomedical Research Initiative</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Silva</surname><given-names>M Catarina</given-names></name><name><surname>Ferguson</surname><given-names>Fleur M</given-names></name><name><surname>Nandi</surname><given-names>Ghata</given-names></name><name><surname>Patnaik</surname><given-names>Debasis</given-names></name><name><surname>Gray</surname><given-names>Nathanael S</given-names></name><name><surname>Haggarty</surname><given-names>Stephen J</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA214608</award-id><principal-award-recipient><name><surname>Donovan</surname><given-names>Katherine A</given-names></name><name><surname>Fischer</surname><given-names>Eric S</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA218278</award-id><principal-award-recipient><name><surname>Donovan</surname><given-names>Katherine A</given-names></name><name><surname>Fischer</surname><given-names>Eric S</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Eric S Fischer is a Damon Runyon-Rachleff Innovator supported in part by the Damon Runyon Cancer Research Foundation (DRR-50-18).</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>M Catarina Silva, is a co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).</p></fn><fn fn-type="conflict" id="conf3"><p>Fleur M Ferguson, is a co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).</p></fn><fn fn-type="conflict" id="conf4"><p>Quan Cai, is a co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).</p></fn><fn fn-type="conflict" id="conf5"><p>Bradford C Dickerson, is a consultant for Merck, Lilly, Biogen, and Piramal; and receives royalties from Oxford University Press, Cambridge University Press, and Elsevier.</p></fn><fn fn-type="conflict" id="conf6"><p>Eric S Fischer, is a SAB member and equity holder in C4 Therapeutics and a consultant to Novartis, AbbVie, and Pfizer. The Fischer lab receives or has received research funding from Novartis, Astellas and Deerfield.</p></fn><fn fn-type="conflict" id="conf7"><p>Nathanael S Gray, is a founder, science advisory board member (SAB) and equity holder in Gatekeeper, Syros, Petra, C4, B2S and Soltego. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Her2llc, Deerfield and Sanofi. Co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).</p></fn><fn fn-type="conflict" id="conf8"><p>Stephen J Haggarty, is a member of the SAB and equity holder in Rodin Therapeutics, Psy Therapeutics, and Frequency Therapeutics. His laboratory has received funding from the Tau Consortium, F-Prime Biomedical Research Initiative, AstraZeneca, JW Pharmaceuticals and speaking fees from AstraZeneca, Amgen, Merck. Co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Mass spectrometry global proteomics data is available via the PRIDE archive, under the project accession number PXD012515. Source data files have been provided for Figures 2, 5 and 7.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Fischer E</collab></person-group><year iso-8601-date="2019">2019</year><source>Targeted Degradation of Aberrant Tau in Frontotemporal Dementia Patient-Derived Neuronal Cell Models</source><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD012515">https://www.ebi.ac.uk/pride/archive/projects/PXD012515</ext-link><comment>PRIDE, PXD012515</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-45457-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>